• In late June 2026, Exelixis, Inc. was removed from three Russell 1000 Defensive-style indexes just as it reported final subgroup overall survival results from its pivotal STELLAR-303 trial of investigational kinase inhibitor zanzalintinib in metastatic colorectal cancer and advanced its related FDA review.
• The mixed picture of a statistically significant overall survival benefit in the full trial population, a non-significant trend in a key subgroup, and an analyst downgrade on pipeline uncertainty has sharpened investor attention on how much of Exelixis’s future depends on successfully broadening beyond CABOMETYX.
• Against this backdrop, we’ll examine how the analyst downgrade tied to zanzalintinib’s regulatory and commercial uncertainty reshapes Exelixis’s investment narrative.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

Exelixis Investment Narrative Recap

To own Exelixis today, you need to believe that management can use cash flows from CABOMETYX to build a second growth pillar around zanzalintinib and other pipeline assets. The Russell 1000 defensive index removals do not directly affect the core business, but they may amplify trading volatility around the FDA’s December 2026 decision on zanzalintinib, which now looks like the key near term catalyst and focal point for pipeline risk.

The most relevant recent announcement here is the final STELLAR 303 subgroup data for zanzalintinib in metastatic colorectal cancer, which showed a clear overall survival benefit in the full trial population but a non significant trend in the non liver metastases subgroup. Those nuances, combined with the ongoing FDA review, help explain why at least one analyst cited pipeline uncertainty and why future readouts across the broader zanzalintinib program are so important to watch.

Yet behind the headline trial win, there is a risk investors should be aware of around how much of Exelixis’s next phase hinges on zanzalintinib’s...

Exelixis' narrative projects $3.3 billion revenue and $1.2 billion earnings by 2029.

Uncover how Exelixis' forecasts yield a $49.65 fair value, a 11% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming Exelixis could grow revenue to about US$3.8 billion and earnings to US$1.8 billion by 2028, which contrasts sharply with concerns that setbacks in trials like STELLAR 305 could slow diversification. These higher expectations may prove too hopeful or could still be achievable, and the latest zanzalintinib news is the kind of development that might reshape which of these views you find more convincing.

Explore 7 other fair value estimates on Exelixis - why the stock might be worth 13% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Exelixis research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Exelixis research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Exelixis' overall financial health at a glance.

No Opportunity In Exelixis?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• We've uncovered the 7 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.